MedTrace Logo

Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

NCT02308254 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-10-29

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of the drug lixisenatide on blood sugar levels, stomach emptying, blood pressure and heart rate, release of gut hormones and blood flow in the gut after a glucose drink in both healthy subjects and people with type 2 diabetes. If lixisenatide is shown to be effective, it would encourage ongoing evaluation of its potential use in the management of the falls in blood pressure following a meal in diabetic patients.

Conditions

Interventions

DRUG

Lixisenatide

Abdominal administration

DRUG

Placebo

Abdominal administration

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Royal Adelaide Hospital

    lead OTHER

Principal Investigators

  • Karen L Jones, PhD · University of Adelaide, Royal Adelaide Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02308254 on ClinicalTrials.gov